Recordati stock holds steady as investors weigh rare disease pipeline

Recordati Industria Chimica e Farmaceutica S.p.A. (ISIN IT0003828271) stock is trading in a stable range as of August 14, 2026, with investors focusing on the group’s rare disease portfolio and development plans in metabolic disorders.

Market context for Recordati shares

According to a recent overview of Recordati trading on the Tradegate venue, the shares were quoted at 52.60 EUR as of August 14, 2026, reflecting a 5-day change of -0.57 percent and a year-to-date performance of +8.28 percent. Recent market data for Recordati This places the stock comfortably above its level at the beginning of the year, even after a modest pullback over the most recent week.

On the over-the-counter markets in the United States, a separate snapshot shows Recordati’s shares quoted at $14.48 USD, with a 5-day change of +9.14 percent and a year-to-date move of -5.90 percent as of August 13, 2026. Performance of Recordati OTC shares The contrast between the positive short-term momentum and the negative performance for the year underscores that investors have recently turned more constructive after a weaker start to 2026.

Rare disease pipeline as a medium-term driver

Beyond near-term share price moves, attention is increasingly directed to Recordati’s work in metabolic and rare endocrine disorders. In coverage of post-bariatric hypoglycemia, Recordati is highlighted as developing pasireotide, an insulin secretion-blocking peptide administered before meals to manage excessive insulin responses in this patient group. Discussion of post-bariatric hypoglycemia therapies Earlier in 2026, Phase 2 results showed an increase in post-meal blood glucose in treated patients, an important signal that the therapy may help prevent symptomatic hypoglycemia.

The company expects to complete a Phase 3 development plan for pasireotide in post-bariatric hypoglycemia by the end of 2026, giving investors a clear regulatory and clinical milestone to watch over the coming quarters. The move from Phase 2 to a fully defined Phase 3 program often implies increased spending in clinical operations, but it also brings the potential for a future commercial asset in a niche area of metabolic disease.

Comparative performance and investor takeaways

Recent data show that Recordati’s EUR-denominated shares have gained 8.28 percent year-to-date while its USD-denominated over-the-counter listing has declined 5.90 percent over the same period. This difference highlights how currency translation and listing venue can affect perceived performance, even when the underlying business is the same. For investors who hold the stock through different markets, monitoring both lines can help reconcile total returns.

The short-term pattern is also notable: the EUR listing shows a mild 5-day decline of 0.57 percent as of August 14, 2026, whereas the USD line shows a 9.14 percent gain over the 5-day period ending August 13, 2026. A move of that magnitude in the OTC shares suggests either a catch-up rally or renewed interest among US-based investors following the Phase 2 data and pipeline commentary.

Representative product: pasireotide for PBH

Pasireotide is a peptide-based therapy focused on blocking insulin secretion in patients who experience excessive insulin release after bariatric surgery, a condition that can cause dangerous drops in blood glucose. In the Phase 2 study mentioned in recent reporting, patients receiving pasireotide experienced higher post-meal blood glucose levels, indicating that the drug may blunt the overshoot in insulin response and stabilize glycemia. Recordati’s intention to finalize a Phase 3 development plan by late 2026 suggests that the company sees commercial potential in this rare metabolic indication, which complements its broader rare disease and specialty medicine portfolio.

Recordati stock and current trading picture

With its home-market shares trading at 52.60 EUR as of August 14, 2026 and delivering an 8.28 percent gain since the start of the year, Recordati presents a picture of steady appreciation backed by a pipeline that now includes advanced development work in post-bariatric hypoglycemia. On the US OTC markets, the $14.48 USD quote as of August 13, 2026 and the 9.14 percent 5-day gain indicate that recent weeks have brought renewed buying interest, even though the year-to-date performance remains negative at -5.90 percent. For investors, the combination of solid year-to-date gains in Europe and improving short-term momentum in the US, alongside a progressing Phase 3 plan for pasireotide, frames Recordati as a specialty pharma name where rare disease development could be a meaningful medium-term driver.

Fact box

Company: Recordati Industria Chimica e Farmaceutica S.p.A.
ISIN: IT0003828271
Ticker: REC
Exchange: Milan (home listing), OTC Markets (secondary USD line)
Price (as of August 14, 2026, 4:02 p.m. ET, Tradegate reference): 52.60 EUR
Market cap: not specified in available same-day sources
Sector / Industry: Pharmaceuticals / Specialty and rare diseases
Index membership: not confirmed in the available same-day sources